These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 23167815)

  • 61. An Investigational RNAi Therapeutic Targeting Glycolate Oxidase Reduces Oxalate Production in Models of Primary Hyperoxaluria.
    Liebow A; Li X; Racie T; Hettinger J; Bettencourt BR; Najafian N; Haslett P; Fitzgerald K; Holmes RP; Erbe D; Querbes W; Knight J
    J Am Soc Nephrol; 2017 Feb; 28(2):494-503. PubMed ID: 27432743
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Clinical spectrum of primary hyperoxaluria type 1: Experience of a tertiary center.
    Soliman NA; Nabhan MM; Abdelrahman SM; Abdelaziz H; Helmy R; Ghanim K; Bazaraa HM; Badr AM; Tolba OA; Kotb MA; Eweeda KM; Fayez A
    Nephrol Ther; 2017 May; 13(3):176-182. PubMed ID: 28161266
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Multiple mechanisms of action of pyridoxine in primary hyperoxaluria type 1.
    Fargue S; Rumsby G; Danpure CJ
    Biochim Biophys Acta; 2013 Oct; 1832(10):1776-83. PubMed ID: 23597595
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Targeting kidney inflammation as a new therapy for primary hyperoxaluria?
    Martin-Higueras C; Ludwig-Portugall I; Hoppe B; Kurts C
    Nephrol Dial Transplant; 2019 Jun; 34(6):908-914. PubMed ID: 30169827
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Recent advances in the identification and management of inherited hyperoxalurias.
    Sas DJ; Harris PC; Milliner DS
    Urolithiasis; 2019 Feb; 47(1):79-89. PubMed ID: 30535828
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Patients with primary hyperoxaluria type 2 have significant morbidity and require careful follow-up.
    Garrelfs SF; Rumsby G; Peters-Sengers H; Erger F; Groothoff JW; Beck BB; Oosterveld MJS; Pelle A; Neuhaus T; Adams B; Cochat P; Salido E; Lipkin GW; Hoppe B; Hulton SA;
    Kidney Int; 2019 Dec; 96(6):1389-1399. PubMed ID: 31685312
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Future treatments for hyperoxaluria.
    Burns Z; Knight J; Fargue S; Holmes R; Assimos D; Wood K
    Curr Opin Urol; 2020 Mar; 30(2):171-176. PubMed ID: 31895888
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Recovery From Dialysis in Patients With Primary Hyperoxaluria Type 1 Treated With Pyridoxine: A Report of 3 Cases.
    Lorenz EC; Lieske JC; Seide BM; Olson JB; Mehta R; Milliner DS
    Am J Kidney Dis; 2021 May; 77(5):816-819. PubMed ID: 32891627
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Transplantation for Primary Hyperoxaluria Type 1: Designing New Strategies in the Era of Promising Therapeutic Perspectives.
    Devresse A; Cochat P; Godefroid N; Kanaan N
    Kidney Int Rep; 2020 Dec; 5(12):2136-2145. PubMed ID: 33305106
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Long-term complications of systemic oxalosis in children-a retrospective single-center cohort study.
    Ben-Shalom E; Cytter-Kuint R; Rinat C; Becker-Cohen R; Tzvi-Behr S; Goichberg J; Peles V; Frishberg Y
    Pediatr Nephrol; 2021 Oct; 36(10):3123-3132. PubMed ID: 33651179
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Nedosiran Dramatically Reduces Serum Oxalate in Dialysis-Dependent Primary Hyperoxaluria 1: A Compassionate Use Case Report.
    Shee K; Ahn J; Hamouche F; Mena J; Chi T; Stoller ML
    Urology; 2021 Oct; 156():e147-e149. PubMed ID: 33774044
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1.
    Garrelfs SF; Frishberg Y; Hulton SA; Koren MJ; O'Riordan WD; Cochat P; Deschênes G; Shasha-Lavsky H; Saland JM; Van't Hoff WG; Fuster DG; Magen D; Moochhala SH; Schalk G; Simkova E; Groothoff JW; Sas DJ; Meliambro KA; Lu J; Sweetser MT; Garg PP; Vaishnaw AK; Gansner JM; McGregor TL; Lieske JC;
    N Engl J Med; 2021 Apr; 384(13):1216-1226. PubMed ID: 33789010
    [TBL] [Abstract][Full Text] [Related]  

  • 73. A randomised Phase I/II trial to evaluate the efficacy and safety of orally administered Oxalobacter formigenes to treat primary hyperoxaluria.
    Hoppe B; Niaudet P; Salomon R; Harambat J; Hulton SA; Van't Hoff W; Moochhala SH; Deschênes G; Lindner E; Sjögren A; Cochat P
    Pediatr Nephrol; 2017 May; 32(5):781-790. PubMed ID: 27924398
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Infant primary hyperoxaluria type 1
    Zheng Y; Li Q; Liang S
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2024 Jun; 49(6):856-862. PubMed ID: 39311781
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Monogenic features of urolithiasis: A comprehensive review.
    Koo KC; Halawani A; Wong VKF; Lange D; Chew BH
    Asian J Urol; 2024 Apr; 11(2):169-179. PubMed ID: 38680588
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Primary hyperoxaluria type 1 in children: clinical and laboratory manifestations and outcome.
    Wannous H
    Pediatr Nephrol; 2023 Aug; 38(8):2643-2648. PubMed ID: 36917293
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Effect of liver transplantation with primary hyperoxaluria type 1: Five case reports and review of literature.
    Wang XY; Zeng ZG; Zhu ZJ; Wei L; Qu W; Liu Y; Tan YL; Wang J; Zhang HM; Shi W; Sun LY
    World J Clin Cases; 2023 Feb; 11(5):1068-1076. PubMed ID: 36874433
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Searching glycolate oxidase inhibitors based on QSAR, molecular docking, and molecular dynamic simulation approaches.
    Cabrera N; Cuesta SA; Mora JR; Paz JL; Márquez EA; Espinoza-Montero PJ; Marrero-Ponce Y; Pérez N; Contreras-Torres E
    Sci Rep; 2022 Nov; 12(1):19969. PubMed ID: 36402831
    [TBL] [Abstract][Full Text] [Related]  

  • 79.
    Martinez-Turrillas R; Martin-Mallo A; Rodriguez-Diaz S; Zapata-Linares N; Rodriguez-Marquez P; San Martin-Uriz P; Vilas-Zornoza A; Calleja-Cervantes ME; Salido E; Prosper F; Rodriguez-Madoz JR
    Mol Ther Methods Clin Dev; 2022 Jun; 25():137-146. PubMed ID: 35402636
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Long-Term Transplantation Outcomes in Patients With Primary Hyperoxaluria Type 1 Included in the European Hyperoxaluria Consortium (OxalEurope) Registry.
    Metry EL; Garrelfs SF; Peters-Sengers H; Hulton SA; Acquaviva C; Bacchetta J; Beck BB; Collard L; Deschênes G; Franssen C; Kemper MJ; Lipkin GW; Mandrile G; Mohebbi N; Moochhala SH; Oosterveld MJS; Prikhodina L; Hoppe B; Cochat P; Groothoff JW;
    Kidney Int Rep; 2022 Feb; 7(2):210-220. PubMed ID: 35155860
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.